Literature DB >> 26002387

Left ventricular hypertrophy and arrhythmogenesis.

Mohammad Shenasa1, Hossein Shenasa2, Nabil El-Sherif3.   

Abstract

Left ventricular hypertrophy (LVH) poses an independent risk of increased morbidity and mortality, including atrial arrhythmias, ventricular arrhythmias, and sudden cardiac death. The most common causes of LVH are hypertension and valvular heart disease. Electrocardiography and echocardiography are the first steps in the diagnosis and evaluation of therapy in patients with LVH. Cardiac MRI is the gold standard in diagnosis and assessment of response to therapy. Management of LVH should be based on etiology, evidence, and guideline adherence. Timely and optimal management of the underlying cause of LVH results in improvement (regression) of LVH and its related complications.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arrhythmogenesis; Atrial fibrillation; Hypertension; Hypertensive heart disease; Left ventricular hypertrophy; Torsades de pointes; Ventricular arrhythmias

Mesh:

Year:  2015        PMID: 26002387     DOI: 10.1016/j.ccep.2015.03.017

Source DB:  PubMed          Journal:  Card Electrophysiol Clin        ISSN: 1877-9182


  16 in total

1.  QT interval instability and variability in dogs with naturally-occurring hypercortisolism.

Authors:  Beatriz de Carvalho Pato Vila; Marcela Sigolo Vanhoni; Marlos Gonçalves Sousa
Journal:  Vet Res Commun       Date:  2022-05-16       Impact factor: 2.459

Review 2.  Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.

Authors:  Jonathan P Law; Luke Pickup; Davor Pavlovic; Jonathan N Townend; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2022-09-22       Impact factor: 2.877

Review 3.  Intersection Between Chronic Kidney Disease and Cardiovascular Disease.

Authors:  Luke J Laffin; George L Bakris
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

Review 4.  Antihypertensive therapy and sudden cardiac death, should we expect the unexpected?

Authors:  Elias Sanidas; Konstantinos Malliaras; Dimitrios Papadopoulos; Maria Velliou; Konstantinos Tsakalis; Kanella Zerva; John Barbetseas
Journal:  J Hum Hypertens       Date:  2020-01-14       Impact factor: 3.012

Review 5.  Conventional and new electrocardiographic criteria for hypertension-mediated cardiac organ damage: A narrative review.

Authors:  Francesca Miceli; Vivianne Presta; Barbara Citoni; Flaminia Canichella; Ilaria Figliuzzi; Andrea Ferrucci; Massimo Volpe; Giuliano Tocci
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-11-06       Impact factor: 3.738

6.  Black-White Differences in Incident Fatal, Nonfatal, and Total Coronary Heart Disease.

Authors:  Lisandro D Colantonio; Christopher M Gamboa; Joshua S Richman; Emily B Levitan; Elsayed Z Soliman; George Howard; Monika M Safford
Journal:  Circulation       Date:  2017-07-11       Impact factor: 29.690

Review 7.  Biology of the cardiac myocyte in heart disease.

Authors:  Angela K Peter; Maureen A Bjerke; Leslie A Leinwand
Journal:  Mol Biol Cell       Date:  2016-07-15       Impact factor: 4.138

8.  Danqi soft capsule prevents infarct border zone remodelling and reduces susceptibility to ventricular arrhythmias in post-myocardial infarction rats.

Authors:  Shiyu Ma; Jin Ma; Xiaoyi Mai; Xujie Zhao; Liheng Guo; Minzhou Zhang
Journal:  J Cell Mol Med       Date:  2019-06-24       Impact factor: 5.310

Review 9.  Evaluation of cardiac hypertrophy in the setting of sudden cardiac death.

Authors:  Kristopher S Cunningham; Danna A Spears; Melanie Care
Journal:  Forensic Sci Res       Date:  2019-08-19

Review 10.  Missing Link between Molecular Aspects of Ventricular Arrhythmias and QRS Complex Morphology in Left Ventricular Hypertrophy.

Authors:  Ljuba Bacharova
Journal:  Int J Mol Sci       Date:  2019-12-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.